Aktis Oncology (NASDAQ:AKTS – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $34.19 and last traded at $32.3590, with a volume of 1211861 shares. The stock had previously closed at $30.11.
Wall Street Analyst Weigh In
Several research firms have commented on AKTS. Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Raymond James Financial started coverage on Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price on the stock. William Blair began coverage on Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating on the stock. Finally, HC Wainwright increased their price target on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.00.
Aktis Oncology Trading Up 7.5%
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last announced its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The company had revenue of $1.87 million for the quarter. Research analysts expect that Aktis Oncology will post -1.62 EPS for the current fiscal year.
Aktis Oncology Company Profile
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
See Also
- Five stocks we like better than Aktis Oncology
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
